← Back
Data updated: Jun 28, 2026
RB HLTH
Specialty Pharmaceuticals
RB HLTH is a specialty pharmaceutical company with 5 FDA-approved products.
1982
Since
5
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
5 Small Molecules
RB HLTH's Key Drugs
RB HLTH's core commercial portfolio centers on MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM — its most strategically important drugs approved in the last 15 years.
RB HLTH's Recent FDA Approvals
RB HLTH secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
RB HLTH's Therapeutic Areas
Disease areas where RB HLTH has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
RB HLTH Pipeline Snapshot
Active clinical trials for RB HLTH across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1982-10-08
- Latest
- 2025-12-22
- Applications
- 5